StockData

Natera vs Veracyte

NTRA and VCYT side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NTRA and VCYT compare

Natera is the larger company, worth 21 times as much as Veracyte ($41.4B against $1.9B).

Natera grew revenue faster over the last twelve months (37.8% versus 17.3% for Veracyte).

Veracyte keeps more of each dollar of sales as profit, with a net margin of 20.4% compared with −7.1% at Natera.

Veracyte scores higher on the StockData Score (16 against 10 for Natera), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNTRAVCYT
Size and price
Market cap$41.4B$1.9B
Share price$287.47$24.23
Change, 1 year40.7%−38.4%
Change, 5 years204%−41.7%
Beta (5Y)1.811.92
Employees6,140755
StockData Score
Total score1016 (better)
Valuation score04 (better)
Growth score33
Performance score23 (better)
Health score56 (better)
Dividend score00
Valuation
P/E–17.3×
P/S15.3×3.5× (better)
P/B22.7×1.4× (better)
EV/EBITDA–13.0×
P/FCF492×11.7× (better)
FCF yield0.20%8.5% (better)
Fair value$120.81$36.51
Margin of safety−138%33.6% (better)
Growth
Revenue growth (TTM)37.8% (better)17.3%
Revenue growth, 5Y average42.6% (better)34.5%
Net income growth (TTM)–335%
EPS growth (TTM)–324%
Profitability
Gross margin–71.7%
Operating margin−10.7%18.8% (better)
Net margin−7.1%20.4% (better)
FCF margin3.1%29.5% (better)
Return on equity−12.5%8.8% (better)
Return on invested capital−40.8%10.0% (better)
Financial health
Debt / equity0.04 (better)0.00
Interest coverage−75.9×–
Current ratio3.009.16 (better)
Altman Z-score29.36 (better)12.65
Piotroski F-score57 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions95.2%111%
Held by insiders3.9%1.7%
Insider net buying, 12 months−$342M−$18.6M (better)
Superinvestors holding3–
Short interest, % of float4.4%12.1%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.